文献速递临床试验与 GCP真实世界研究与卫生经济流行病学与生物统计

欧洲快速审批框架下数字医疗器械的创新临床试验评价方法

Innovative Clinical Trial Approach for Evaluating Digital Medical Devices Under European Fast-Track Regulatory Frameworks.
PubMed 文献 · Stat Med · 2026-01-01

针对欧盟部分HTA机构为数字医疗器械提供的过渡性准入路径(仅有不完整临床试验数据、CE认证后仍存在显著不确定性),提出整合临床试验数据与真实世界数据的统计框架。框架含临床试验期中分析、最终分析及两者Meta分析三步,并用模拟研究评估,建议上市后评价补充。

要点

  • 过渡性准入下可整合临床试验与真实世界数据支持最终决策
  • 框架分期中分析、最终分析及Meta分析三步
  • 提出优化期中分析时机与临时授权申请的指标

核心结论

  • 提出适用于欧洲HTA快速审批要求的数字医疗器械评价统计框架,整合临床试验数据与真实世界数据。

研究设计与样本

  • 方法学框架研究,通过广泛模拟研究评估所提框架。

主要发现

  • 框架包括临床试验数据期中分析、临床试验数据最终分析及合并临床试验数据与真实世界数据的Meta分析三步。
  • 引入若干指标以优化期中分析时机和临时授权申请。

临床怎么用

  • 期中分析可支持临时监管授权并启动真实世界数据收集,最终分析后与真实世界数据Meta分析支持最终决策。
  • 器械广泛采用后应补充上市后评价,符合IV期研究原则。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

To address patient demand for rapid access to innovative digital medical devices (DMDs), several health technology assessment (HTA) authorities in European Union countries provide transitional or provisional access and reimbursement pathways. These pathways are available when only incomplete clinical trial data are accessible, and significant uncertainty remains regarding the clinical benefits, even after CE (European conformity) marking has been obtained. Once manufacturers complete the clinical studies, additional real-world data (RWD) may become available as a result of the device's use in the target population. Consequently, regulators can draw on both sources of information to support their final decision-making processes. For a statistically principled evaluation of such settings, we propose a statistical framework suitable for DMD evaluation under European HTA fast-track requirements, integrating both clinical trial data and RWD. The framework consists of three key steps: (1) an interim analysis of clinical trial data, which can support temporary regulatory authorization and enable the collection of RWD; (2) a final analysis of the clinical trial data; and (3) a meta-analysis combining the clinical trial data and RWD, contingent upon obtaining temporary authorization. To optimize the timing of the interim analysis and the application for temporary authorization, we introduce several metrics. The proposed framework was assessed by means of an extensive simulation study. This framework should be complemented by a post-market evaluation of the DMD once it has been widely adopted, aligning with the principles of phase IV studies.

来源:Stat Med,查看原文。版权归原作者所有。

引用

  1. Ursino M, Boulet S, Collignon C, et al. Innovative Clinical Trial Approach for Evaluating Digital Medical Devices Under European Fast-Track Regulatory Frameworks. Stat Med. 2026. PMID: 42086335. doi:10.1002/sim.70572

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。